Schizophrenia Mental and Behavioural Disorders Schizophrenia
Conditions
Interventions
Intervention group: Adherence therapy (AT)+ Treatment as usual
Control group: Treatment as usual
Patients in the interventions group receive eight sessions of adherence therapy as an add-on to treatm
Sponsors
Clinic of Psychiatry and Psychotherapy Bethel (Germany)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients between 18 and 65 years old 2. Patients with schizophrenia will be enrolled when the initial acute psychotic symptoms are reduced (partial remission) from a clinical point of view so that they were able to provide a written informed consent 3. Clinical diagnosis of schizophrenia will be confirmed by a research diagnosis of schizophrenia, established using the International Diagnostic Checklist for ICD-10 4. Patients will be taking antipsychotic medication at the time of recruitment, and the current treating psychiatrist has recommended the individual patient to stay on antipsychotic medication for a minimum of one year.
Exclusion criteria
Exclusion criteria: 1. Potential study participants will be excluded if they show acute suicidal behaviours including suicidal ideas 2. Insufficient German language capacities 3. Are administered depot medication 4. Are homeless, or suffered from a current substance or alcohol dependence (not caffeine or nicotine dependence) or mental retardation according to International Classification of Diseases (ICD-10) and Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) criteria. 5. Patients are under compulsory treatment, if they are homeless or suffer from severe medical conditions (eg. cancer, severe infection)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Adherence - determined using drug serum levels (concentration to dose ratio) 2. Symptoms - measured using the postive and negative syndrome scale Measured at baseline and 26 week follow-up | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Attitudes to treatment - assessed using the drug attitude inventory 2. Functioning - determined using the global assessment of functioning Measured at baseline and 26 week follow-up | — |
Countries
Switzerland
Outcome results
None listed